The US FDA has approved an apomorphine hydrochloride wearable subcutaneous infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). The infusion device provides continuous treatment during the waking day. Clinical evidence In a clinical trial, apomorphine hydrochloride demonstrated a significant reduction in daily OFF time at 12 weeks compared to a placebo (2.6 vs. 0.9 hours).

Additionally, apomorphine hydrochloride significantly increased GOOD ON time compared to the placebo (2.8 vs. 1.1 hours). Furthermore, a significantly higher percentage of apomorphine hydrochloride-treated patients (79%) reported general health improvement compared to 24% in the placebo group. Dosage and administration A subcutaneous infusion device Provides continuous treatment during the waking day Warnings and precautions Blood clots Nausea and vomiting…